BRCA1 and breast carcinoma: Those with the lowest likelihood of BRCA1/2 by Manchester score had a 3-fold higher rate of non-BRCA genes whereas those with predicted rates of ~80% had 5-fold higher rate of BRCA1/2. Unless those referring patients with breast cancer for extended panel testing are certain there is no loss of sensitivity for BRCA1/2 they should opt of a bespoke BRCA1/2 test first in those with high prior likelihoods of BRCA1/2 pathogenic variants.